Search clinical trials for: fludarabine/ melphalan

Total 2132 results

Masonic Cancer Center, University of Minnesota

Active, not recruiting

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

United States
Glycostem Therapeutics BV

Recruiting

Registry of Patients Having Received oNKord®

AML

Switzerland, Germany
Wuhan Union Hospital, China
Beijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.

Recruiting

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

T-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin Lymphoma

China
Wuhan Union Hospital, China
Shanghai Simnova Biotechnology Co.,Ltd.

Recruiting

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Non Hodgkin's Lymphoma

China
The Korean Society of Pediatric Hematology Oncology

Unknown

Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)

Aplastic Anemia

Korea, Republic of
St. Jude Children's Research Hospital

Completed

Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia (AACD34)

Aplastic Anemia

United States
Chinese PLA General Hospital
Peking University; EdiGene Inc.

Recruiting

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Non Hodgkin's Lymphoma

China
M.D. Anderson Cancer Center
Kite, A Gilead Company; Acerta Pharma, LLC

Recruiting

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Lymphoma | Mantle Cell Lymphoma

United States
Changchun Deng, MD

Active, not recruiting

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Non Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center

Completed

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Lymphoma | Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma

Unilateral Retinoblastoma

United States
Medsearch

Unknown

Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

Sarcoma | Melanoma (Skin)

United States
Tehran University of Medical Sciences

Unknown

131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma

Neuroblastoma

Iran, Islamic Republic of
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Plasma Cell Tumors

China
Institut Paoli-Calmettes

Unknown

Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes (CEREAL)

Leukemia, Myeloid, Acute | Leukemia, Lymphoblastic, Acute

France
Emory University

Completed

Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies

Hematologic Malignancies

United States
Chinese PLA General Hospital
309th Hospital of Chinese People's Liberation Army; Beijing Naval General Hospital and other collaborators

Unknown

Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Leukemia
University of Alabama at Birmingham

Terminated

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin's Lymphoma | CLL / SLL | Waldenstroms

United States
University of Chicago
National Cancer Institute (NCI)

Recruiting

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Hematologic Malignancy

United States
St. Jude Children's Research Hospital

Terminated

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Myeloid Sarcoma | Chronic Myelogenous Leukemia (CML) | Non-Hodgkin Lymphoma (NHL) | Juvenile Myelomonocytic Leukemia (JMML)

United States
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Lymphoma | Leukemia

China
Sun Yat-sen University

Unknown

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Ovarian Cancer

China
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
Baylor College of Medicine
The Methodist Hospital Research Institute

Terminated

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Sickle Cell Anemia | Thalassemia | Hemoglobinopathy

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); GlaxoSmithKline

Completed

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

Multiple Myeloma

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
The Cleveland Clinic

Completed

Rituximab in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fondazione EMN Italy Onlus

Terminated

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients (D-MP)

Myeloma

Italy
University of California, San Diego
Jazz Pharmaceuticals

Terminated

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

AML | AML, Adult | Acute Myeloid Leukemia, Adult

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Multiple Myeloma

China
University of Michigan Rogel Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Multiple Myeloma | Plasma Cell Leukemia

United States
Alice Bertaina
California Institute for Regenerative Medicine (CIRM)

Recruiting

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

CKD Stage 4 | Cystinosis | FSGS | SLE Nephritis | SIOD

United States
Chinese PLA General Hospital

Recruiting

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Non-hodgkin Lymphoma

China
M.D. Anderson Cancer Center

Terminated

Study of Gelonin Purging of Autologous Stem Cells for Transplantation

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent... and other conditions

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Leukemia | Thrombocytopenia | Fanconi Anemia | Congenital Amegakaryocytic Thrombocytopenia | Severe Congenital Neutropenia | Diamond-blackfan Anemia

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Lymphoma

United States
Cabaletta Bio

Recruiting

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy

Idiopathic Inflammatory Myopathy | Dermatomyositis | Immune-Mediated Necrotizing Myopathy | Anti-Synthetase Syndrome

United States
HRYZ Biotech Co.

Recruiting

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Cervical Cancer | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | Anal Carcinoma | Vagina Tumor | Carcinoma of Penis | Carcinoma of Vulva

China
The Christie NHS Foundation Trust

Terminated

A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy (CD19)

CD19 Positive Non-Hodgkin Lymphoma

United Kingdom
Institut Paoli-Calmettes
Agence de La Biomédecine

Completed

Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases (BX-PK)

Hematological Diseases

France
German CLL Study Group
University of Cologne; MedacSchering Onkologie

Completed

Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

B-cell Chronic Lymphocytic Leukemia

Germany
CancerCare Manitoba
The Leukemia and Lymphoma Society

Terminated

HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Canada
Sun Yat-sen University
Fudan University; West China Hospital; Peking University Cancer Hospital & Institute and other collaborators

Unknown

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

Mantle Cell Lymphoma Recurrent

China
HRYZ Biotech Co.

Recruiting

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Cervical Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Carcinoma of Penis | Carcinoma of Vulva | Carcinoma of Vagina

China
Institute of Hematology & Blood Diseases Hospital
Bejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...

Recruiting

Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Refractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, Childhood

China
Wuhan Union Hospital, China
Chengdu USino Technology Biology Co., Ltd

Recruiting

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

China

Search clinical trials for: fludarabine/ melphalan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations